Spinal Muscular Atrophy Treatment Market Trends

The ongoing innovation and advancement in gene therapy and other treatments for spinal muscular atrophy are anticipated to propel market growth during the analysis period. For instance, animal data presented in 2022 at the American Society of Gene and Cell Therapy (ASGCT), the European Society of Gene and Cell Therapy (ESGCT), and the World Muscle Congress showed that the gene therapy outperformed the benchmark therapy across multiple key endpoints in a mouse model of SMA and exhibited significantly less liver toxicity when administered intravenously. Thus, ongoing research into next-generation gene therapies and small molecule drugs is expanding the range of treatment options, attracting more investment and interest in the market, which is expected to contribute to its growth.